In another study of 24 advanced-stage NSCLC patients treated with Nivolumab, CTCs were analyzed for PD-L1 expression at baseline, 3, and 6 months post therapy initiation [95]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.